JDJennifer A. Doll

Jennifer A. Doll

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jennifer A. Doll has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Frank K. Reiher

    Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, Illinois

    1 shared publication
  • Michael R. Pins

    Department of Pathology, Northwestern University Medical School, Chicago, Illinois

    1 shared publication
  • Noël P. Bouck

    Department of Microbiology‐Immunology, Northwestern University Medical School, Chicago, Illinois

    1 shared publication
  • Steven C. Campbell

    Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, Illinois

    1 shared publication
  • Susan E. Crawford

    Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, Illinois

    1 shared publication

Latest Publications

  • Thrombospondin‐1, vascular endothelial growth factor and fibroblast growth factor‐2 are key functional regulators of angiogenesis in the prostate

    by Jennifer A. Doll, Frank K. Reiher, Susan E. Crawford, Michael R. Pins, Steven C. Campbell, Noël P. Bouck

    Background: Prostate cells secrete many molecules capable of regulating angiogenesis; however, which of these actually function as essential regulators of neovascularization is not yet clear.Methods: Functional angiogenic mediators secreted by normal and diseased prostate cells were identified using an in vitro angiogenesis assay. These factors were quantified by immunoblot or ELISA and localized in tissue by immunohistochemistry.Results: Normal prostate epithelial cell secretions were anti‐angiogenic due to inhibitory thrombospondin‐1 (TSP‐1) whereas this inhibitor was decreased in the pro‐angiogenic secretions derived from benign prostatic hyperplasia (BPH) and cancer cells. This pro‐angiogenic activity depended primarily on fibroblast growth factor‐2 (FGF‐2) and/or vascular endothelial growth factor (VEGF) whose secretion was increased. Immunolocalization studies confirmed that the changes detected in vitro also occurred in vivo.Conclusions: During disease progression in the prostate, production of TSP‐1, the major inhibitor, is down‐regulated while that of stimulatory FGF‐2 and/or VEGF rise, leading to the induction of the new vessels necessary to support tumor growth. Prostate 49:293–305, 2001.